Conductive Hydrogel Delivery for Scarred Myocardium Conduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ventricular arrhythmias, such as implantable cardiac defibrillators, are costly, painful, and ineffective in preventing re-entrant arrhythmias, and there is a need for a treatment that can restore electrical conduction across scarred myocardium without causing further cardiac damage.
Innovation Solution
A conductive hydrogel is delivered via a catheter into the myocardial vasculature, where it cures in situ to form a flexible, biostable, and conductive pathway across scarred myocardium, allowing for improved electrical conduction and reducing the need for defibrillation shocks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If implantable cardiac defibrillators are used to treat ventricular arrhythmias, then cardiac rhythm management is achieved, but the treatment becomes costly and causes painful shocks
Solution Approach 1:
The patent introduces a conductive hydrogel as an intermediary substance delivered via catheter into the myocardium. This hydrogel serves as a mediator between the electrical stimulation source and the scarred myocardial tissue, enabling electrical conduction restoration without requiring painful defibrillation shocks. The hydrogel fills the gap created by scar tissue and provides a conductive pathway for electrical signals.
Solution Approach 2:
The invention changes the physical and electrical parameters of the scarred myocardium by introducing a conductive hydrogel material. This material alters the electrical conductivity and mechanical properties of the scarred region, transforming it from a non-conductive barrier into a conductive pathway that allows normal electrical propagation through the myocardium.
2Reliability
If antiarrhythmic drugs are used to slow conduction velocity, then re-entrant wavefronts are prevented, but toxic side effects occur
Solution Approach 1:
The conductive hydrogel acts as a physical intermediary that restores electrical conduction through scarred tissue without requiring pharmacological intervention. Unlike antiarrhythmic drugs that chemically alter conduction velocity throughout the heart, the hydrogel provides a localized conductive pathway only where needed, eliminating systemic toxicity while achieving the same arrhythmia prevention effect.
3Reliability
If ablation is performed to destroy diseased tissue, then arrhythmia substrate is removed, but recurrent arrhythmia and collateral damage occur
Solution Approach 1:
Instead of destroying the scarred tissue through ablation, the invention converts the harmful scar tissue into a beneficial conductive pathway by infusing it with conductive hydrogel. This approach transforms the arrhythmia substrate from a source of re-entrant wavefronts into a restored conduction pathway, eliminating the need for tissue destruction and avoiding associated collateral damage and recurrence.
4Reliability
If defibrillation shocks are delivered to terminate arrhythmia, then cardiac rhythm is restored, but extensive collateral damage occurs
Solution Approach 1:
The conductive hydrogel is delivered preliminarily into the myocardium before arrhythmia occurs or during elective procedures. By pre-establishing conductive pathways through scarred tissue, the hydrogel prevents the formation of re-entrant wavefronts in the first place, eliminating the need for subsequent defibrillation shocks and their associated collateral damage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogel restores electrical conduction across scarred myocardium, potentially eliminating re-entrant arrhythmias and reducing the power required for defibrillation, thereby preventing sudden cardiac death and improving cardiac rhythm management.
Implementation Method 1
A conductive hydrogel is delivered via a catheter into the myocardial vasculature, where it cures in situ to form a flexible, biostable, and conductive pathway
Data Source
Figure 1~2A
Figure 2B~2C
Figure 3
AI summary
A conductive hydrogel precursor solution cures after injection into the vasculature of the myocardium. The vasculature acts as a mold for the hydrogel and allows for a pacing signal to be conducted across the myocardium and not at a single point like traditional pacing leads. The catheter-based delivery can accurately place the hydrogels into the myocardial veins and can fill the venous tributaries. In situ crosslinking of the hydrogel precursor solution is achieved through several mechanisms, such as redox initiation by mixing a reducing reagent and oxidizing agent after injection. Conductivity is achieved by doping in conductive polymers or other conductive elements such as ionic species, metallic nanoparticles, or graphene nanoplatelets. To ensure long-term conductivity, hydrogel macromers may be synthesized without hydrolytically labile groups such as esters, and the conductive elements may be conjugated directly to the hydrogel matrix.